Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2017 | ZUMA-1: a pivotal trial of axicabtagene ciloleucel (AXI-CEL; KTE-C19) in patients with NHL

Yi Lin • 5 Jul 2017
EHA 2017
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Axicabtagene ciloleucel CAR-T
ZUMA-1

Dr Yi Lin from Mayo Clinic, Rochester, USA describes the results of the ZUMA-1 trial in patients with refractory non-Hodgkin lymphoma (NHL), who currently have a very poor outcome. The study met it’s primary endpoint with regard to response rate and the investigators found common immunotherapy toxicities and side effects, which they felt were manageable and tolerable. This video was recorded at the European Society of Hematology meeting in Madrid, Spain.

More from Yi Lin

1:59
Factors to consider when choosing between cilta-cel and ide-cel for R/R multiple myeloma
Yi Lin • 9 Dec 2023
1:50
Real-world outcomes of teclistamab treatment in R/R multiple myeloma
Yi Lin • 9 Dec 2023
1:32
AEs associated with CAR-T in patients with triple-class exposed R/R MM: analysis from KarMMa-3
Yi Lin • 9 Dec 2023
3:04
Outpatient monitoring following CAR-T and BsAb treatment for patients with lymphoma and MM
Yi Lin • 9 Dec 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals